how rational are COX-2 inhibitors?

[Guest guest]

Dear Members,Selectivity

for COX-2 reduces the risk of peptic ulceration, and is the main feature of celecoxib, rofecoxib

and other members of this drug class. COX-2 selectivity does not seem to reduce

other adverse effects of NSAIDs (most notably an increased risk of renal

failure), and some results have shown an increase in the risk for heart attack,

thrombosis and stroke by a relative increase in thromboxane.

Rofecoxib was taken off the market in 2004 because

of these concerns.

Dr.

K. Jaiswal

Lecturer,

Dept of Pharmacology.

GMC,

Nagpur.